Home Biosimilar Antibodies Others Others Amatuximab (Anti-Mesothelin)
For research use only. Not for use in humans.

Amatuximab (Anti-Mesothelin)

Synonyms: MORab-009

Amatuximab (Anti-Mesothelin) is a chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed in many epithelial-derived cancer cells. MW: 145.5 kD.

Amatuximab (Anti-Mesothelin)

Quality Control

Batch: Purity: 99% Protein concentration: 5.68mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Amatuximab (Anti-Mesothelin) is a chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed in many epithelial-derived cancer cells. MW: 145.5 kD.

Product Details

CAS No. 931402-35-6
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06885697 RECRUITING Drug: cyclophosphamide|Drug: fludarabine Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms National Cancer Institute (NCI) 2025-07-08 PHASE1
NCT07010523 RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide Mesothelin-positive Advanced Malignant Solid Tumors First Affiliated Hospital of Zhejiang University 2024-10-15
NCT05848999 UNKNOWN Mesothelin-positive Advanced Malignant Solid Tumors Zhejiang University 2023-04-27 PHASE1
NCT05531708 WITHDRAWN Drug: Fludarabine|Drug: Cyclophosphamide Mesothelin-positive Advanced Refractory Solid Tumors Shanghai Pudong Hospital 2021-04-02 PHASE1
NCT05783089 NOT_YET_RECRUITING Mesothelin-positive Advanced Malignant Solid Tumors Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2023-04 PHASE1
NCT05775666 UNKNOWN Solid Tumor Peking University 2023-03 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.